ID: ALA2387019

Max Phase: Preclinical

Molecular Formula: C20H24N4O3

Molecular Weight: 368.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC(CC)c1nn(CC)c2c1N=C(c1ccc(C(=O)O)cc1)CNC2=O

Standard InChI:  InChI=1S/C20H24N4O3/c1-4-12(5-2)16-17-18(24(6-3)23-16)19(25)21-11-15(22-17)13-7-9-14(10-8-13)20(26)27/h7-10,12H,4-6,11H2,1-3H3,(H,21,25)(H,26,27)

Standard InChI Key:  NMWZIECWRMDJED-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 368.44

Molecular Weight (Monoisotopic): 368.1848

AlogP: 3.37

#Rotatable Bonds: 6

Polar Surface Area: 96.58

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.94

CX Basic pKa: 0.93

CX LogP: 3.09

CX LogD: -0.10

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.82

Np Likeness Score: -0.48

References

1. Plummer MS, Cornicelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, Lu XK, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S..  (2013)  Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.,  23  (11): [PMID:23582272] [10.1016/j.bmcl.2013.03.072]

Source

Source(1):

• Scientific Literature